Back

Notification report


Full notification file


General information

Notification Number
B/ES/11/25

Member State to which the notification was sent
Spain

Date of acknowledgement from the Member State Competent Authority
08/04/2011

Title of the Project
Phase I-II therapeutic vaccination clinical trial in patients with chronic hepatitis C by administration of autologous dendritic cells transduced with an adenoviral vector encoding NS3 protein

Proposed period of release:
08/04/2011 to 31/12/2013

Name of the Institute(s) or Company(ies)
ClĂ­nica Universidad de Navarra, ;


3. Is the same GMO release planned elsewhere in the Community?
Not known

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
AdNS3 is a recombinant defective adenovirus derived form human adenovirus type 5

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Human adenovirus type 5MastadenovirusHuman adenovirus type 5Type C adenovirus

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
01/07/2011 00:00:00
Remarks: